PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9613746-6	1998	Treatment with ACTH was associated with significant correlations between dopaminergic markers such as HVA, dihydroxyphenylacetic acid (DOPAC), and Dopa.	3,4-Dihydroxyphenylacetic Acid	107-133	proopiomelanocortin	Homo sapiens	15-19	
9613746-6	1998	Treatment with ACTH was associated with significant correlations between dopaminergic markers such as HVA, dihydroxyphenylacetic acid (DOPAC), and Dopa.	3,4-Dihydroxyphenylacetic Acid	135-140	proopiomelanocortin	Homo sapiens	15-19	
6087372-4	1984	The morphine induced increase of striatal DOPAC (3,4-dihydroxyphenylacetic acid) content was also inhibited by ACTH treatment, however, neither the analgesia, nor the hypermotility caused by morphine were affected.	3,4-Dihydroxyphenylacetic Acid	42-47	proopiomelanocortin	Homo sapiens	111-115	
6087372-4	1984	The morphine induced increase of striatal DOPAC (3,4-dihydroxyphenylacetic acid) content was also inhibited by ACTH treatment, however, neither the analgesia, nor the hypermotility caused by morphine were affected.	3,4-Dihydroxyphenylacetic Acid	49-79	proopiomelanocortin	Homo sapiens	111-115	
6255276-0	1980	Reduction by beta-endorphin of efflux of dopamine and DOPAC from superfused medial basal hypothalamus.	3,4-Dihydroxyphenylacetic Acid	54-59	proopiomelanocortin	Homo sapiens	13-27	
743624-2	1978	The initial injection of beta-endorphin results in increases in the dopamine metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), in neostriatum, as well as increases in the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), in hypothalamus and brainstem and a decrease in 5-HIAA in hippocampus.	3,4-Dihydroxyphenylacetic Acid	90-120	proopiomelanocortin	Homo sapiens	25-39	
743624-2	1978	The initial injection of beta-endorphin results in increases in the dopamine metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), in neostriatum, as well as increases in the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), in hypothalamus and brainstem and a decrease in 5-HIAA in hippocampus.	3,4-Dihydroxyphenylacetic Acid	122-127	proopiomelanocortin	Homo sapiens	25-39	
905630-1	1977	Acute intraventricular administration of human beta-endorphin increased 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) concentrations in rat striatum at a time when the catatonic effect was also present.	3,4-Dihydroxyphenylacetic Acid	72-102	proopiomelanocortin	Homo sapiens	47-61	
567367-1	1978	Acute intracisternal administration of human beta-endorphin produced catalepsy and increased striatal concentrations of 3,4-dihydroxyphenylacetic acid (DOPA) and homovanillic acid (HVA).	3,4-Dihydroxyphenylacetic Acid	120-150	proopiomelanocortin	Homo sapiens	45-59	
567367-1	1978	Acute intracisternal administration of human beta-endorphin produced catalepsy and increased striatal concentrations of 3,4-dihydroxyphenylacetic acid (DOPA) and homovanillic acid (HVA).	3,4-Dihydroxyphenylacetic Acid	152-156	proopiomelanocortin	Homo sapiens	45-59	
567367-4	1978	The combination of subcataleptic doses of haloperidol and beta-endorphin produced catalepsy and large increases in striatal DOPAC and HVA.	3,4-Dihydroxyphenylacetic Acid	124-129	proopiomelanocortin	Homo sapiens	58-72	
905630-1	1977	Acute intraventricular administration of human beta-endorphin increased 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) concentrations in rat striatum at a time when the catatonic effect was also present.	3,4-Dihydroxyphenylacetic Acid	104-109	proopiomelanocortin	Homo sapiens	47-61